Document is current
Any future updates will be listed below
-
Authors
Zysman, Maéva https://orcid.org/0000-0003-1459-2409
Herman, Fanchon
Grassion, Léo https://orcid.org/0000-0002-1909-9755
Taillé, Camille
Gonzalez-Bermejo, Jesus
Guecamburu, Marina https://orcid.org/0009-0007-7719-7453
Roche, Nicolas
Pavot, Arthur
Girodet, Pierre-Olivier
Bourdin, Arnaud
Molinari, Nicolas
Berger, Patrick
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05037929 at ClinicalTrials.govnct04053634 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S1 Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO
https://doi.org/10.1136/thorax-2025-btsabstracts.7
nct03930732 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct04456673 at ClinicalTrials.govDocuments that mention this clinical trial
P189 Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema
https://doi.org/10.1136/thorax-2024-btsabstracts.350
M14 Association between early lung function improvement with dupilumab and sustained clinical outcomes in patients with chronic obstructive pulmonary disease: a clinical perspective
https://doi.org/10.1136/thorax-2025-btsabstracts.498
M15 Dupilumab efficacy across baseline eosinophil counts in patients with chronic obstructive pulmonary disease with type 2 inflammation
https://doi.org/10.1136/thorax-2025-btsabstracts.499
Dupilumab in chronic obstructive pulmonary disease
https://doi.org/10.1136/dtb.2026.000013
S174 Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease
https://doi.org/10.1136/thorax-2025-btsabstracts.180
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
M13 Antibiotic and systemic corticosteroid use in patients with chronic obstructive pulmonary disease and type 2 inflammation receiving dupilumab
https://doi.org/10.1136/thorax-2025-btsabstracts.497
S31 Efficacy of dupilumab in chronic obstructive pulmonary disease with type 2 inflammation by baseline blood eosinophil count
https://doi.org/10.1136/thorax-2023-btsabstracts.37
S94 Dupilumab improves quality of life in patients with moderate-to-severe COPD and type 2 inflammation in phase 3 BOREAS trial
https://doi.org/10.1136/thorax-2024-btsabstracts.100
S101 Impact of dupilumab in patients with chronic obstructive pulmonary disease with cardiovascular or metabolic comorbidities: BOREAS and NOTUS trials
https://doi.org/10.1136/thorax-2025-btsabstracts.107
P190 Dupilumab improves patient-reported respiratory symptoms in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial
https://doi.org/10.1136/thorax-2024-btsabstracts.351
nct05326412 at ClinicalTrials.govDocuments that mention this clinical trial
M14 Association between early lung function improvement with dupilumab and sustained clinical outcomes in patients with chronic obstructive pulmonary disease: a clinical perspective
https://doi.org/10.1136/thorax-2025-btsabstracts.498
S93 Phase 3 NOTUS trial: dupilumab efficacy and safety in patients with moderate-to-severe chronic obstructive pulmonary disease and type 2 inflammation
https://doi.org/10.1136/thorax-2024-btsabstracts.99
M15 Dupilumab efficacy across baseline eosinophil counts in patients with chronic obstructive pulmonary disease with type 2 inflammation
https://doi.org/10.1136/thorax-2025-btsabstracts.499
Dupilumab in chronic obstructive pulmonary disease
https://doi.org/10.1136/dtb.2026.000013
S174 Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease
https://doi.org/10.1136/thorax-2025-btsabstracts.180
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
M13 Antibiotic and systemic corticosteroid use in patients with chronic obstructive pulmonary disease and type 2 inflammation receiving dupilumab
https://doi.org/10.1136/thorax-2025-btsabstracts.497
S101 Impact of dupilumab in patients with chronic obstructive pulmonary disease with cardiovascular or metabolic comorbidities: BOREAS and NOTUS trials
https://doi.org/10.1136/thorax-2025-btsabstracts.107
nct04133909 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct04039113 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05166889 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05158387 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial
https://doi.org/10.1136/thorax-2024-btsabstracts.97
nct06040086 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial
https://doi.org/10.1136/thorax-2024-btsabstracts.97
nct05037929 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial
https://doi.org/10.1136/thorax-2024-btsabstracts.97
nct04053634 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S1 Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO
https://doi.org/10.1136/thorax-2025-btsabstracts.7
nct03930732 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05326412 at ClinicalTrials.govDocuments that mention this clinical trial
P189 Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema
https://doi.org/10.1136/thorax-2024-btsabstracts.350
M14 Association between early lung function improvement with dupilumab and sustained clinical outcomes in patients with chronic obstructive pulmonary disease: a clinical perspective
https://doi.org/10.1136/thorax-2025-btsabstracts.498
M15 Dupilumab efficacy across baseline eosinophil counts in patients with chronic obstructive pulmonary disease with type 2 inflammation
https://doi.org/10.1136/thorax-2025-btsabstracts.499
Dupilumab in chronic obstructive pulmonary disease
https://doi.org/10.1136/dtb.2026.000013
S174 Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease
https://doi.org/10.1136/thorax-2025-btsabstracts.180
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
M13 Antibiotic and systemic corticosteroid use in patients with chronic obstructive pulmonary disease and type 2 inflammation receiving dupilumab
https://doi.org/10.1136/thorax-2025-btsabstracts.497
S31 Efficacy of dupilumab in chronic obstructive pulmonary disease with type 2 inflammation by baseline blood eosinophil count
https://doi.org/10.1136/thorax-2023-btsabstracts.37
S94 Dupilumab improves quality of life in patients with moderate-to-severe COPD and type 2 inflammation in phase 3 BOREAS trial
https://doi.org/10.1136/thorax-2024-btsabstracts.100
S101 Impact of dupilumab in patients with chronic obstructive pulmonary disease with cardiovascular or metabolic comorbidities: BOREAS and NOTUS trials
https://doi.org/10.1136/thorax-2025-btsabstracts.107
P190 Dupilumab improves patient-reported respiratory symptoms in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial
https://doi.org/10.1136/thorax-2024-btsabstracts.351
nct04133909 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct04039113 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05166889 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05158387 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial
https://doi.org/10.1136/thorax-2024-btsabstracts.97
nct05037929 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial
https://doi.org/10.1136/thorax-2024-btsabstracts.97
nct04053634 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S1 Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO
https://doi.org/10.1136/thorax-2025-btsabstracts.7
nct03930732 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05326412 at ClinicalTrials.govDocuments that mention this clinical trial
P189 Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema
https://doi.org/10.1136/thorax-2024-btsabstracts.350
M14 Association between early lung function improvement with dupilumab and sustained clinical outcomes in patients with chronic obstructive pulmonary disease: a clinical perspective
https://doi.org/10.1136/thorax-2025-btsabstracts.498
M15 Dupilumab efficacy across baseline eosinophil counts in patients with chronic obstructive pulmonary disease with type 2 inflammation
https://doi.org/10.1136/thorax-2025-btsabstracts.499
Dupilumab in chronic obstructive pulmonary disease
https://doi.org/10.1136/dtb.2026.000013
S174 Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease
https://doi.org/10.1136/thorax-2025-btsabstracts.180
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
M13 Antibiotic and systemic corticosteroid use in patients with chronic obstructive pulmonary disease and type 2 inflammation receiving dupilumab
https://doi.org/10.1136/thorax-2025-btsabstracts.497
S31 Efficacy of dupilumab in chronic obstructive pulmonary disease with type 2 inflammation by baseline blood eosinophil count
https://doi.org/10.1136/thorax-2023-btsabstracts.37
S94 Dupilumab improves quality of life in patients with moderate-to-severe COPD and type 2 inflammation in phase 3 BOREAS trial
https://doi.org/10.1136/thorax-2024-btsabstracts.100
S101 Impact of dupilumab in patients with chronic obstructive pulmonary disease with cardiovascular or metabolic comorbidities: BOREAS and NOTUS trials
https://doi.org/10.1136/thorax-2025-btsabstracts.107
P190 Dupilumab improves patient-reported respiratory symptoms in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial
https://doi.org/10.1136/thorax-2024-btsabstracts.351
nct04133909 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct04039113 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05166889 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
nct05158387 at ClinicalTrials.govDocuments that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial
https://doi.org/10.1136/thorax-2024-btsabstracts.97
Documents that mention this clinical trial
What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
https://doi.org/10.1136/bmjresp-2024-002702
S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial
https://doi.org/10.1136/thorax-2024-btsabstracts.97
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (Not applicable)
Chiesi Foundation
Astra Zeneca
Sanofi (not appicable)
- License Information
